Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Public financial snapshot
Amounts retain their original currency and units. Consolidated group revenue is not standalone CRO/CDMO service revenue. Year-to-date periods are not standalone quarters.
Period
Currency / basis
Revenue
Net profit
Operating cash flow
Report
FY2025 2025-12-31
CNY PRC Accounting Standards / consolidated
1,364,990,550.76
-245,969,313.48 Net income attributable to shareholders of the listed company
Financials represent the listed group’s consolidated totals. Diversified group revenue is not CRO/CDMO segment revenue.
Some reported year-over-year earnings changes use a loss base. Interpret them alongside the earnings sign and whether the company moved to a loss or narrowed a loss.
2026Q3 (YTD) · Reporting notes
Financials represent the listed group’s consolidated totals. Diversified group revenue is not CRO/CDMO segment revenue.
Some reported year-over-year earnings changes use a loss base. Interpret them alongside the earnings sign and whether the company moved to a loss or narrowed a loss.
Unaudited. Hong Kong interim reports and A-share nine-month reports cover different periods.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
A diversified testing group including pharmaceutical testing/CRO; financials cover all testing businesses.
The full 2025 annual report and the 2026 first-nine-month report have been obtained.
Program / service
Target / indication
Representative stage
Evidence & scope
Outsourced services/custom R&D (group also sells products)
Services / platform
Evidence of services, not clinical data for a drug candidate
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Fresenius signed an exclusive development agreement with WuXi Biologics providing access to up to 37 biosimilar candidates over the next decade. Initial work is expected to focus on polatuzumab vedotin and teprotumumab biosimilars. Fresenius retains selection flexibility and commercialization economics; the candidate count is an option-based opportunity, not 37 approved products.
Biocytogen reported consolidated revenue of RMB1.403 billion, up 49.09%, and attributable net income of RMB312.4 million for the nine months ended September 30, 2026. Attributable net income increased 173.77%. The group combines animal models, research services, and antibody licensing activities. The quarterly filing is unaudited and covers the year-to-date period.
PharmaBlock Sciences reported consolidated revenue of RMB1.634 billion, up 15.16%, and attributable net income of RMB151.2 million for the nine months ended September 30, 2026. Attributable net income rose 33.36%, while net cash from operations declined 53.75% over the same period. The quarterly filing is unaudited and covers the year-to-date period.
Complete service-segment revenue, orders, capacity utilization, and project conversion rates have not been separately verified. Group totals are not a substitute for segment figures.
